Product information and disease descriptionProduct descriptionProduct information
Product comparison
31 evidence topics · 33 sources
Summary: lorundrostat and the add-on options for uncontrolled hypertension
- Approved add-on drugs with a labeled hypertension indication: baxdrostat (BAXFENDY, aldosterone synthase inhibitor, FDA-approved May 2026, 1 mg or 2 mg once daily), aprocitentan (TRYVIO, endothelin receptor antagonist, 12.5 mg once daily, boxed warning for embryo-fetal toxicity), spironolactone (ALDACTONE, labeled “as add-on therapy for the treatment of hypertension”), and eplerenone (INSPRA, 50 mg once daily, up to 50 mg twice daily). Two renal denervation systems received FDA premarket approval in November 2023 as “adjunctive treatment” when lifestyle modifications and antihypertensive medications do not control blood pressure.
- Placebo-adjusted change in office systolic blood pressure in the pivotal trials: baxdrostat -9.8 mmHg (2 mg) and -8.7 mmHg (1 mg) at week 12 in BaxHTN; aprocitentan 12.5 mg -3.8 mmHg at week 4; lorundrostat 50 mg -9.1 mm Hg at week 6 in Launch-HTN. The trials differ in time point, measurement method, and background therapy, and no head-to-head trial of lorundrostat against another add-on drug was identified.
- Indirect comparisons: in a drug-level network meta-analysis of 10 trials (2,865 participants) with resistant hypertension, the mean differences in office systolic blood pressure versus placebo were -14.08 mmHg (amiloride), -10.78 mmHg (spironolactone), -9.09 mmHg (baxdrostat), -8.14 mmHg (eplerenone), and -6.80 mmHg (lorundrostat). ICER rated the evidence “insufficient” (I) for baxdrostat versus lorundrostat in all three of its populations, “Promising but Inconclusive” (P/I) for either drug versus spironolactone, eplerenone, or amiloride in Populations 1 and 2, and “comparable or inferior” (C-) versus amlodipine in Population 3.
- Hyperkalemia in ICER's comparison table: baxdrostat 6.6% (1 mg) and 10.2% (2 mg) against 2.5% with placebo; lorundrostat 50 mg 2.5% against 0.3% with placebo.
Lorundrostat: Launch-HTN primary endpoint, for comparison with the add-on drugs below
“For the pooled 50 mg of lorundrostat group (n = 808), the least-squares mean change in automated office systolic BP at week 6 was −16.9 mm Hg (95% CI, −19.0 to −14.9 mm Hg) vs −7.9 mm Hg (95% CI, −11.5 to −4.2 mm Hg) for the placebo group (least-squares mean difference, −9.1 mm Hg [95% CI, −13.3 to −4.9 mm Hg]; P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baxdrostat (BAXFENDY, AstraZeneca): FDA approval, May 2026
Baxdrostat (BAXFENDY): prescribing information
Baxdrostat: BaxHTN primary endpoint in the prescribing information, seated systolic blood pressure at week 12
| Systolic blood pressure (mmHg) | BAXFENDY 2 mg | BAXFENDY 1 mg | Placebo |
|---|---|---|---|
| Participants | “n=266” | “n=264” | “n=263” |
| Baseline (mean) | “149.1” | “149.7” | “149.0” |
| Change from baseline (mean) | “-15.7” | “-14.5” | “-5.8” |
| Difference from placebo (95% CI) | “-9.8 (-12.6, -7.0)” | “-8.7 (-11.5, -5.8)” | |
| p-value vs. placebo | “< 0.0001” | “< 0.0001” |
Baxdrostat: BaxHTN publication
“794 participants were randomized to and received baxdrostat 1mg (n=264), baxdrostat 2mg (n=266), or placebo (n=264) in addition to background therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimated treatment differences for baxdrostat 1mg and 2mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and – 9.8 mmHg (–12.6 to –7.0; P<0.0001), respectively. Potassium >6.0 mmol/l occurred in 6 participants (2.3%) with baxdrostat 1mg, 8 (3.0%) with baxdrostat 2mg, and 1 (0.4%) with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baxdrostat: Bax24 trial, 24-hour ambulatory systolic blood pressure in resistant hypertension
“At 12 weeks, the change from baseline in the least-squares mean 24 h ambulatory SBP was -16·6 mm Hg (95% CI -18·8 to -14·3) in the baxdrostat group (n=89) and -2·6 mm Hg (-4·7 to -0·4) in the placebo group (n=95); the estimated placebo-corrected difference was -14·0 mm Hg (-17·2 to -10·8; p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A confirmed potassium level of more than 6 mmol/L occurred in three (3%) of the 108 baxdrostat recipients and in none of the placebo recipients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baxdrostat: adverse reactions in the pooled 12-week placebo-controlled periods
Baxdrostat: CHMP positive opinion in the European Union, November 2026
Baxdrostat: anticipated FDA action date, December 2025, superseded by approval in May 2026
Aprocitentan (TRYVIO, Idorsia): prescribing information
Aprocitentan: PRECISION primary endpoint in the prescribing information, sitting systolic blood pressure at week 4
| Sitting systolic blood pressure (mmHg) | TRYVIO 12.5 mg | Placebo |
|---|---|---|
| Participants | “243” | “244” |
| Baseline | “153.2” | “153.3” |
| LS mean change (97.5% CL) | “−15.4 (−17.5, −13.3)” | “−11.6 (−13.7, −9.5)” |
| Difference to placebo, LS mean (97.5% CL) | “−3.8 (−6.8, −0.8)” | “–” |
| p-value | “0.0043” | “–” |
Aprocitentan: REMS removed, April 2025
Aprocitentan: commercial availability and approvals outside the United States
Spironolactone (ALDACTONE): prescribing information
Spironolactone: PATHWAY-2 trial in drug-resistant hypertension
“The average reduction in home systolic blood pressure by spironolactone was superior to placebo (–8·70 mm Hg [95% CI −9·72 to −7·69]; p<0·0001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In six of the 285 patients who received spironolactone, serum potassium exceeded 6·0 mmol/L on one occasion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eplerenone (INSPRA): prescribing information
| Field | Quoted label text |
|---|---|
| Indication | “INSPRA is indicated for the treatment of hypertension in adults, to lower blood pressure.” |
| Dosage in hypertension | “The recommended starting dose of INSPRA is 50 mg administered once daily.” |
| Dose increase | “For patients with an inadequate blood pressure response to 50 mg once daily increase the dosage of INSPRA to 50 mg twice daily.” |
| Contraindications for hypertension | “type 2 diabetes with microalbuminuria,” |
| Contraindications for hypertension | “creatinine clearance <50 mL/min, or” |
| Mechanism | “Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone” |
Amiloride: randomized comparison with spironolactone in resistant hypertension
“In this open-label, blinded end-point, randomized clinical trial involving 118 patients with resistant hypertension, amiloride and spironolactone lowered home-measured systolic blood pressure by 13.6 mm Hg and 14.7 mm Hg from baseline, respectively, with no difference in blood pressure–lowering effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vicadrostat (BI 690517, Boehringer Ingelheim): investigational aldosterone synthase inhibitor studied with empagliflozin
“BI 690517 dose-dependently reduced albuminuria with concurrent renin-angiotensin system inhibition and empagliflozin, suggesting an additive efficacy for chronic kidney disease treatment without unexpected safety signals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Zilebesiran (Alnylam and Roche): investigational subcutaneous siRNA against angiotensinogen
“The least-squares mean difference between zilebesiran and placebo in change from baseline to 3 months in 24-hour mean ambulatory SBP was −12.1 mm Hg (95% CI, −16.5 to −7.6; P < .001) for indapamide, −9.7 mm Hg (95% CI, −12.9 to −6.6; P < .001) for amlodipine, and −4.5 mm Hg (95% CI, −8.2 to −0.8; P = .02) for olmesartan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across cohorts, more patients who received zilebesiran than placebo experienced hyperkalemia (18 [5.5%] vs 6 [1.8%]), hypotension (14 [4.3%] vs 7 [2.1%]), and acute kidney failure (16 [4.9%] vs 5 [1.5%]) events, but most episodes were mild and resolved without medical intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LSM differences vs placebo in change from baseline to month 3 were −14.1 mm Hg (95% CI, −19.2 to −9.0; P < .001) with zilebesiran, 150 mg, once every 6 months; −16.7 mm Hg (95% CI, −21.2 to −12.3; P < .001) with zilebesiran, 300 mg, once every 3 months or every 6 months; and −15.7 mm Hg (95% CI, −20.8 to −10.6; P < .001) with zilebesiran, 600 mg, once every 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renal denervation: FDA premarket approvals, November 2023
Renal denervation: Medicare coverage with evidence development
Renal denervation: sham-controlled trials
“At 24 months, the RDN group experienced significantly greater mean reductions in ambulatory systolic BP (−12.1±15.3 mm Hg [n=176] versus −7.0±13.1 mm Hg [n=33]; difference: −5.7 mm Hg; P=0.039) and office systolic BP (−17.4±16.1 mm Hg [n=187] versus −9.0±19.4 mm Hg [n=35]; difference: −8.7 mm Hg; P=0.0034) compared with sham controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The reduction in daytime ambulatory SBP was greater with ultrasound renal denervation (mean, −7.9 mm Hg [SD, 11.6 mm Hg]) vs the sham procedure (mean, −1.8 mm Hg [SD, 9.5 mm Hg]) (baseline-adjusted between-group difference, −6.3 mm Hg [95% CI, −9.3 to −3.2 mm Hg], P < .001), with a consistent effect of ultrasound renal denervation throughout the 24-hour circadian cycle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drug-level network meta-analysis in resistant hypertension: office systolic blood pressure
“Ten RCTs including 2865 participants were analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MDs versus placebo were −14.08 mmHg for amiloride (95% CI, −17.40 to −10.77), −10.78 mmHg for spironolactone (95% CI, −13.14 to −8.42), −9.09 mmHg for baxdrostat (95% CI, −11.29 to −6.88), −8.14 mmHg for eplerenone (95% CI, −14.56 to −1.72), and −6.80 mmHg for lorundrostat (95% CI, −8.47 to −5.13).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MDs were −10.88 mmHg for MRAs (95% CI, −13.29 to −8.48) and −7.56 mmHg for ASIs (95% CI, −9.24 to −5.89).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although newer ASIs may provide meaningful short‐term BP reductions, equivalence with MRAs cannot be inferred from the current evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, safety outcomes were not quantitatively compared because adverse event reporting was incomplete and inconsistent across trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indirect comparison of lorundrostat and baxdrostat by the Bucher method
“Five placebo-controlled RCTs (N = 2599) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lower-dose pair was statistically equivalent (lorundrostat 50 mg vs. baxdrostat 1 mg: mean difference (MD), +0.63 mmHg; P = 0.645); baxdrostat 2 mg produced a modest but significant advantage over lorundrostat 100 mg (MD, +3.56 mmHg; P = 0.043).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both agents markedly increased hyperkalemia risk (lorundrostat pooled risk ratio (RR), 8.16; baxdrostat pooled RR, 15.12); the between-drug comparison was not significant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bayesian meta-analysis of second-generation aldosterone synthase inhibitors
“Eight RCTs were included (n = 3,369; 2,430 [72%] randomized to ASI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, ASIs increased the odds of hyperkalemia (OR: 7.1; CrI: 3.56, 15.2; τ2 0.23), hyponatremia (OR: 2.6; CrI: 1.25, 5.98; τ2 0.1), and hypotension (OR: 3.28; CrI: 1.43, 8.16; τ2 0.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In subgroup analysis, the probability of achieving a clinically meaningful reduction in SBP (MD < −5 mm Hg) was 87.5% with baxdrostat and 94.3% with lorundrostat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ICER network meta-analysis, Population 1 (resistant hypertension not at goal): systolic blood pressure versus placebo
| Add-on drug | Mean difference versus placebo, mm Hg (95% credible interval) |
|---|---|
| Baxdrostat | “-11 (-14.6, -7.3)” |
| Spironolactone | “-10.1 (-13.1, -6.8)” |
| Lorundrostat | “-9 (-16.3, -1.7)” |
| Eplerenone | “-8.9 (-15.5, -2.4)” |
| Amiloride | “-6.6 (-11.5, -1.5)” |
ICER network meta-analysis, Population 3 (not at goal on two drugs, third first-line agent not yet tried): systolic blood pressure versus placebo
| Add-on drug | Mean difference versus placebo, mm Hg (95% credible interval) |
|---|---|
| Baxdrostat | “-10.1 (-16.6, -3.9)” |
| Lorundrostat | “-8.6 (-12.4, -4.8)” |
| Amlodipine | “-8.3 (-10.7, -6.2)” |
ICER comparative evidence ratings
Hyperkalemia at 12 weeks across aldosterone-pathway drugs
| Drug | Arm | n | Hyperkalemia, % |
|---|---|---|---|
| Baxdrostat | “BAX 1 mg” | “333” | “6.6” |
| Baxdrostat | “BAX 2 mg” | “441” | “10.2” |
| Baxdrostat | “Placebo” | “442” | “2.5” |
| Lorundrostat | “LOR 50 mg” | “635” | “2.5” |
| Lorundrostat | “Placebo” | “367” | “0.3” |
| Spironolactone | “SPIR 15-50 mg” | “2748” | “17.5” |
| Spironolactone | “Placebo” | “2760” | “7.5” |
| Eplerenone | “EPL 25-50 mg” | “5282” | “5” |
| Eplerenone | “Placebo” | “5275” | “2.6” |